Navigating the Algorithmic Frontier: Risk Mitigation and Regulatory Compliance for AI in GMP Environments
[中譯] 領航演算法前沿：GMP 環境下人工智慧的風險減低與法規遵循

1. The Strategic Intersection of AI Innovation and GMP Rigor
[中譯] 1. AI 創新與 GMP 嚴謹度的戰略交會

The pharmaceutical industry stands at a critical strategic crossroads where the promise of unprecedented efficiency through Artificial Intelligence (AI) meets the non-negotiable mandates of Good Manufacturing Practice (GMP).
[中譯] 製藥產業正處於一個關鍵的戰略十字路口，在這裡，透過人工智慧（AI）實現前所未高效率的承諾，面臨了藥品優良製造規範（GMP）不可妥協的強制命令。

For C-suite executives and Quality Assurance directors, the objective is to capture the disruptive value of innovation without eroding the foundational safety standards that preserve patient trust and regulatory standing.
[中譯] 對於 C-Suite 高階主管和品質保證總監而言，其目標是在不侵蝕維護病人信任與法規地位之基礎安全標準的前提下，捕捉創新帶來的顛覆性價值。

However, current industry discourse reveals a fundamental tension: the industry is divided on whether the current generation of Large Language Models (LLMs) and generative AI can ever satisfy the rigorous demands of a validated state.
[中譯] 然而，目前的產業論述揭示了一種根本性的緊張關係：對於現今世代的大型語言模型（LLMs）和生成式 AI 是否能夠滿足確效狀態的嚴格要求，產業內部存在分歧。

While the appetite for automating complex tasks—ranging from deviation assessments to document summarization—is high, the inherent nature of certain AI models poses a direct challenge to traditional validation.
[中譯] 儘管將複雜任務（範圍從偏差評估到文件摘要）自動化的意願很高，但某些 AI 模型固有的本質對傳統驗證提出了直接挑戰。

Regulatory scrutiny is intensifying as industry bodies like the ECA Foundation highlight the gaps between the capabilities of probabilistic models and the rigid expectations of current quality frameworks.
[中譯] 隨著像 ECA 基金會這樣的產業機構強調了機率模型的能力與現行品質架構的嚴格預期之間的差距，法規審查正在逐步加強。

As a strategic advisor, I must emphasize that the path forward requires more than technical experimentation;
[中譯] 作為戰略顧問，我必須強調，前行的道路不僅僅需要技術實驗；

it necessitates a structural realignment of how we define "control" in an era of non-deterministic software.
[中譯] 它還需要在非確定性軟體時代，對我們如何定義「受控狀態」進行結構性調整。

2. The Hallucination Dilemma: Why Generative AI Challenges GMP Principles
[中譯] 2. 幻覺困境：為什麼生成式 AI 挑戰 GMP 原則

The bedrock of pharmaceutical quality is built upon the twin pillars of determinism and reproducibility.
[中譯] 醫藥品質的基石建立在確定性和再現性這兩大支柱之上。

In a GxP environment, a process is only "under control" if specific inputs invariably lead to the same predictable, documented output.
[中譯] 在 GxP 環境中，只有當特定的輸入總是能帶來相同、可預測且經記錄的輸出時，一個程序才被視為處於「受控狀態」。

Generative AI introduces a degree of variability and unpredictability—technically termed "hallucination"—that is fundamentally antithetical to these core tenets.
[中譯] 生成式 AI 引入了一定程度的變異性和不可預測性（在技術上稱為「幻覺」），這與這些核心原則根本上是背道而馳的。

The following table evaluates how the fluid properties of Large Language Models (LLMs) conflict with established GMP requirements:
[中譯] 下表評估了大型語言模型（LLMs）的流動特質如何與已確立的 GMP 要求相衝突：

Fundamental Principle of GMP [中譯] GMP 的根本原則	Property of Generative AI / LLMs [中譯] 生成式 AI / LLM 的屬性	Regulatory Conflict / Impact [中譯] 法規衝突 / 影響
Determinism [中譯] 確定性	Probabilistic Outcomes [中譯] 機率性結果	LLMs function on probability; identical inputs do not guarantee identical outputs. [中譯] LLM 基於機率運作；相同的輸入無法保證相同的輸出。
Reproducibility [中譯] 再現性	Variability & Updates [中譯] 變異性與更新	Responses vary over time; model updates and weight changes alter behavior unexpectedly. [中譯] 回應會隨時間而變；模型更新和權重改變會意外地改變行為。
Traceability [中譯] 可追溯性	Hallucinations [中譯] 幻覺	AI may generate plausible but fabricated information, breaking the chain of truth. [中譯] AI 可能會產生看似合理但實為虛構的資訊，打破真實性的連鎖。
Validability [中譯] 可確效性	Vast State Spaces [中譯] 龐大的狀態空間	State spaces are too enormous to fully test; no complete specification of all possible responses. [中譯] 狀態空間過於龐大而無法完全測試；無法對所有可能的回應進行完整的規格制定。

The risks associated with these technical failures are particularly acute in Batch Record Review. Should an AI system fail during this critical oversight phase, the source context identifies six specific areas where failure results in immediate regulatory risk:
[中譯] 與這些技術失敗相關的風險在批製造紀錄審查中尤為尖銳。如果 AI 系統在這個關鍵的監督階段失敗，原始文獻確定了失敗會導致直接法規風險的六個特定領域：

• Overlooking missing signatures: Compromising accountability.
  [中譯] 遺漏缺失的簽名（經簽署的）：損害可追責性。
• Incorrect thresholds: Allowing batches that violate predefined parameters.
  [中譯] 錯誤的限值：允許違反預定義參數的批次通過。
• Missing deviations or process violations: Failing to flag non-compliance.
  [中譯] 遺漏偏差或程序違反：未能標記不合規情形。
• Inconsistencies across datasets: Missing contradictions in manual vs. automated logs.
  [中譯] 跨數據集的不一致性：遺漏手動日誌與自動日誌之間的矛盾。
• Overlooking OOS/OOT indicators: Failing to identify Out of Specification or Out of Trend data.
  [中譯] 遺漏 OOS/OOT 指標：未能識別規格外（Out of Specification）或趨勢外（Out of Trend）數據。
• Generating plausible but incorrect justifications: Masking a failure with a linguistically convincing but factually wrong rationale.
  [中譯] 產生看似合理但錯誤的辯解：用語言上具有說服力但實際上錯誤的理由來掩蓋失敗。

The danger lies not just in the error itself, but in the lack of "explainability" and the difficulty of formal validation for a system where uncertainty is difficult to quantify. These technical instabilities have directly necessitated the evolving regulatory frameworks we see today.
[中譯] 危險不僅在於錯誤本身，還在於缺乏「可解釋性」，以及對於一個難以量化不確定性的系統進行正式驗證的困難。這些技術不穩定性直接促成了我們今天所看到的演進中之法規架構。

3. The Evolving Regulatory Landscape: EU Annex 22 and the EMA Framework
[中譯] 3. 演進中的法規地景：歐盟 Annex 22 與 EMA 架構

To prevent a compliance vacuum where innovation outpaces patient safety, regulators are codifying the boundaries of AI deployment. The strategic necessity of a unified framework—such as the EU GMP Annex 22 draft (issued July 7, 2025)—is to provide the industry with a roadmap for investment that does not sideline data integrity.
[中譯] 為了防止創新超越病人安全而出現法規遵循真空，法規監管機構正在對 AI 部署的邊界進行編碼規範。統一架構的戰略必要性——例如歐盟 GMP Annex 22 草案（2025年7月7日發布）——是為產業提供一份不以犧牲數據完整性為代價的投資路線圖。

It is critical to note that the current draft of Annex 22 does not apply to dynamic and probabilistic models; rather, it specifies that they should not be used in critical GMP applications.
[中譯] 值得特別注意的是，目前的 Annex 22 草案並不適用於動態和機率模型；相反地，它明確規定它們不應該被用於關鍵的 GMP 應用中。

This distinction creates a de facto exclusion for models that adapt automatically during use or fail to produce deterministic outputs (same input equals same output). For systems with a direct impact on patient safety or product quality, the regulator’s stance remains rooted in "Frozen" or "Static" model parameters.
[中譯] 這一區別對在安裝使用過程中會自動適應或無法產生確定性輸出（相同輸入等於相同輸出）的模型創造了事實上的排除。對於對病人安全或產品品質有直接影響的系統，法規監管機構的立場仍然根植於「凍結」或「靜態」的模型參數。

Furthermore, the EMA’s "Reflection paper on the use of artificial intelligence in the lifecycle of medicines" advocates for a lifecycle approach, moving the industry away from "set-and-forget" software toward continuous monitoring. However, the emergence of these regulations has revealed significant friction points as the industry attempts to reconcile the "slow pace" of regulatory revision with the "disruptive speed" of AI development.
[中譯] 此外，歐洲藥品管理局（EMA）的「在藥品生命週期中使用人工智慧的反思文件」主張採用生命週期方法，使產業擺脫「設定後即忘記」的軟體模式，轉向持續監控。然而，隨著產業試圖調和法規修訂的「慢步伐」與 AI 開發的「顛覆性速度」，這些法規的出現暴露了顯著的摩擦點。

4. Industry Impact and Stakeholder Critique: The Quest for Agility
[中譯] 4. 產業影響與利害關係人評論：尋求敏捷性

Industry feedback is vital to ensure regulations do not stifle the innovation they aim to govern. Major stakeholders, including the ECA Foundation and the European QP Association, have identified several primary concerns regarding the current draft of Annex 22:
[中譯] 產業反饋對於確保法規不會扼殺其旨在治理的創新至關重要。主要利害關係人，包括 ECA 基金會和歐洲 QP 協會，已針對目前的 Annex 22 草案提出了幾個主要關切：

• Speed of AI vs. Regulatory Pace: AI systems undergo disruptive developments in months, while regulatory revisions typically take years.
  [中譯] AI 的速度與法規步伐：AI 系統在幾個月內就會經歷顛覆性的發展，而法規修訂通常需要數年時間。
• The Innovation Gap: A broad exclusion of generative AI might hinder the implementation of solutions that could actually improve overall pharmaceutical quality.
  [中譯] 創新差距：廣泛排除生成式 AI 可能會阻礙那些實際上能提高整體醫藥品質之解決方案的實施。
• Staffing Constraints: Concerns regarding the rigid requirements for test data independence, particularly for smaller organizations.
  [中譯] 人員配置限制：對測試數據獨立性之嚴格要求的擔憂，特別是對於較小的組織。

To address these concerns, stakeholders have proposed a Q&A mechanism to complement Annex 22. This mechanism would provide the agility required for such a dynamic field, allowing for interpretive guidance and updates without the need for full formal revisions of the Annex. Notably, the ECA Foundation has offered to support this process by drafting and submitting proposals for these Q&As, signaling a proactive shift toward industry-regulator collaboration.
[中譯] 為了應對這些擔憂，利害關係人提出了一項 Q&A 機制來補充 Annex 22。該機制將提供這一動態領域所需的敏捷性，允許進行解釋性指引和更新，而無需對附錄進行全面的正式修訂。值得注意的是，ECA 基金會已提議透過起草和提交這些 Q&A 的建議書來支持這一過程，標誌著向產業與監管機構合作的積極轉變。

5. Lessons from Enforcement: The FDA’s Stance on "Blind AI Reliance"
[中譯] 5. 執法教訓：FDA 對「盲目依賴 AI」的立場

Strategic oversight is the only way to avoid the pitfalls of "Warning Letter" territory. The FDA has already signaled that treating AI as a replacement for human judgment—rather than a tool for enhancement—is a violation of statutory duty. The April 2026 FDA Warning Letter to Purolea Cosmetics Lab serves as a landmark case. The FDA deconstructed the lab’s "blind" reliance on AI agents for creating drug specifications and master production records, citing:
[中譯] 戰略監督是避免陷入「警告信」領域的唯一方法。FDA 已經發出信號，將 AI 視為人類判斷的替代品——而非增強工具——是違反法定職責的行為。2026年4月 FDA 發給 Purolea Cosmetics Lab 的警告信是一個里程碑式的案例。FDA 解構了該實驗室對 AI 代理人用於建立藥品規格和主生產紀錄的「盲目」依賴，並引用：

• 21 CFR 211.22(c): Failure of the Quality Unit to review and approve AI-generated drug specifications.
  [中譯] 21 CFR 211.22(c)：品質單位未能審查並核准 AI 生成的藥品規格。
• 21 CFR 211.100: Lack of process validation; the company’s claim that "the AI agent never indicated validation was necessary" was rejected by the agency.
  [中譯] 21 CFR 211.100：缺乏過程確效（製程確效）；該公司聲稱「AI 代理人從未指出驗證是必要的」被該機構駁回。

The FDA’s enforcement confirms a hierarchy of AI use cases:
[中譯] FDA 的執法確認了 AI 使用案例的層級結構：

• Acceptable (Assistance/Prioritization): Semantic search, document summarization, signal detection, and flagging risk indicators.
  [中譯] 可接受（協助/優先級排序）：語意檢索、文件摘要、訊號偵測和標記風險指標。
• Less Commonly Accepted (Autonomous Decision-Making): Autonomous release decisions, independent deviation assessments, or fully automated batch release.
  [中譯] 較少被接受（自主決策）：自主放行決策、獨立的偏差評估，或完全自動化的批次放行。

The failure at Purolea reinforces the mandate: all AI recommendations must be reviewed and approved by an authorized human representative of the Quality Unit.
[中譯] Purolea 的失敗強化了這項強制命令：所有 AI 建議必須由品質單位的授權人類代表進行審查並核准。

6. The "Human-in-the-Loop" (HITL) Framework and Personnel Requirements
[中譯] 6. 「人機協同」（HITL）架構與人員要求

In the modern GMP environment, "Human-in-the-Loop" (HITL) is a mandatory structural component. HITL ensures that while AI processes data at scale, a qualified human provides the critical context and accountability. Annex 22 defines four critical personnel requirements to maintain this oversight:
[中譯] 在現代 GMP 環境中，「人機協同」（HITL）是一個強制的結構性組成部分。HITL 確保在 AI 大規模處理數據的同時，由具備資格的人員提供關鍵的背景脈絡與可追責性。Annex 22 定義了維持此項監督的四個關鍵人員要求：

• Staff Qualification & Cooperation (Chapter 2): Close cooperation between process SMEs, QA, data scientists, and IT is required. All personnel must have defined responsibilities and appropriate access levels.
  [中譯] 人員資格與合作（第 2 章）：需要製程專業領域專家（SMEs）、QA、數據科學家和 IT 之間的密切合作。所有人員必須有明確定義的職責和適當的存取控制級別。
• Documented Performance (Chapter 3): The training and consistent performance of employees making AI-supported decisions must be continuously recorded.
  [中譯] 經記錄的績效（第 3 章）：做出 AI 輔助決策之員工的訓練與一致性績效必須被持續記錄。
• Staff Independence (Chapter 6): Personnel involved in training should not be involved in validation. For smaller organizations where independence is impossible, Annex 22 allows a contingency: an employee who had access to test data must work in a pair (the 4-eyes principle) with a colleague who did not.
  [中譯] 人員獨立性（第 6 章）：參與訓練的人員不應參與驗證。對於無法實現獨立性的較小組織，Annex 22 允許一項權宜措施：曾接觸測試數據的員工必須與未曾接觸的同事組成配對（雙人複核原則 / 4-eyes principle）共同工作。
• Human Review Protocols (Chapter 10): Human review is mandatory whenever the "testing effort for this model has been reduced." Records must be kept to ensure that every output is fit for purpose based on its criticality.
  [中譯] 人類審查協定（第 10 章）：每當「該模型的測試工作量已減少」時，人類審查是強制性的。必須保存記錄以確保根據其關鍵度，每項輸出皆符合預期用途。

Under this paradigm, the Process SME is explicitly responsible for the "adequacy of the description" and "acceptance criteria" (per Sections 3.1 and 4.2). AI identifies anomalies, but the Quality Unit (QU) retains the sole authority to approve and the responsibility for the final decision.
[中譯] 在此範式下，製程專業領域專家（Process SME）依據第 3.1 和 4.2 節明確負責「說明的充分性」與「允收標準」。AI 識別異常，但品質單位（QU）保留核准的唯一權限以及對最終決策的責任。

7. Strategic Mitigation: Building a Validatable AI Architecture
[中譯] 7. 戰略緩解：建立可確效的 AI 架構

At Persimmon Engineering, we advocate for a technical architecture that prioritizes control over "free-form" generation. The strategic shift must be toward rule-based analysis systems integrated directly into the Quality Management System (QMS). To technically reduce risk, organizations must adopt this checklist for a validatable AI architecture:
[中譯] 在梁山工程顧問有限公司(Persimmon Engineering)，我們提倡一種將控制權置於「自由格式」生成之上的技術架構。戰略轉變必須走向直接整合至品質管理系統（QMS）中的基於規則的分析系統。為了在技術上降低風險，組織必須採用這份適用於可確效 AI 架構的檢核表：

• Deterministic Pipelines & Frozen Models: Models must be "Static"—all parameters finally set to ensure same input equals same output.
  [中譯] 確定性管線與凍結模型：模型必須是「靜態的」——所有參數最終設定以確保相同的輸入等於相同的輸出。
• RAG Architectures: Utilize Retrieval-Augmented Generation to pull exclusively from approved SOPs and controlled data.
  [中譯] RAG 架構：利用檢索增強生成（RAG），專門從經核准的 SOP 和受控數據中提取資料。
• Explainability Integration: Systems must capture the features contributing to a decision. Tools like SHAP or LIME should be integrated into the QMS to allow the QU to review the justification for any test result.
  [中譯] 可解釋性整合：系統必須捕捉促成決策的特徵。像 SHAP 或 LIME 這樣的工具應該被整合到 QMS 中，以允許品質單位（QU）審查任何測試結果的理由。
• Confidence Scores & Thresholds: Each classification must log a confidence score. Per Annex 22 Section 9.2, if the score is low, the system must flag the outcome as "undecided," triggering mandatory human intervention.
  [中譯] 信心分數與限值：每項分類必須記錄一個信心分數。根據 Annex 22 第 9.2 節，如果分數過低，系統必須將結果標記為「未決」，從而觸發強制性的人類介入。
• Continuous Revalidation: Establish statistical performance measurements to monitor for drift and ensure input data remains within the model's intended "sample space."
  [中譯] 持續進行的再確效：建立統計績效測量，以監控偏移並確保輸入數據保持在模型預期的「樣本空間」之內。

The future of AI in GMP is not defined by the question, "Can the AI get it right?" The only question that matters for compliance is: "Can you prove to an auditor that the system is controlled, reproducible, and valid?" In the world of GxP, control is the only true currency of innovation.
[中譯] AI 在 GMP 中的未來並非由「AI 能做對嗎？」這個問題來定義。對於合規性而言，唯一重要的問題是：「你能向稽核員證明該系統是受控的、可再現的且有效的嗎？」在 GxP 的世界中，控制是創新唯一的真正貨幣。